X-linked sideroblastic anemia (XLSA) is caused by mutations of the erythroid-specific 6-aminolevulinate synthase gene (ALAS2) resulting in deficient heme synthesis. The characteristic hypochromic, microcytic anemia typically becomes manifest in the first three decades of life. Hematologic response to pyridoxine is variable and rarely complete. We report two unrelated cases of highly pyridoxine-responsive XLSA in geriatric patients previously diagnosed with refractory anemia and ringed sideroblasts. A previously unaffected 77-yr-old male and an 81-yr-old female were each found to have developed severe hypochromic, microcytic anemia with ringed sideroblasts in the bone marrow, which responded dramatically to pyridoxine with normalization of hemoglobin values. Sequence analysis identified an A to C transversion in exon 7 (K299Q) of the ALAS2 gene in the male proband and his daughter. In the female proband a
Introduction
The sideroblastic anemias are a heterogeneous group of disorders that may be either acquired, or less commonly, inherited. All are characterized by ineffective erythropoiesis resulting in anemia of varying severity, elevated serum iron, and the presence of ringed sideroblasts in the bone marrow (1) . The etiology of the sideroblastic anemias is poorly understood. However, the biochemical and molecular basis of the best-documented inherited form, X-linked sideroblastic anemia (XLSA)1 (McKusick No. 301300 [2] ), has recently been characterized. XLSA has been shown to be due to mutations in the erythroidspecific 6-aminolevulinate synthase (ALAS2) gene at Xp 1.21 encoding the first enzyme in the heme biosynthetic pathway (3) (4) (5) (6) (7) (8) (9) . The disease is usually detectable in newborns but may not present clinically until midlife or, rarely, later (1, 10) . Patients generally have severe hypochromic, microcytic anemia with increased iron storage that shows a partial clinical response to pyridoxine ( 1) . A different sideroblastic anemia linked to Xql3 (McKusick No. 301310 [2] ) is associated with ataxia in the two families described to date (11, 12) . Other rare forms of sideroblastic anemia are clearly autosomal ( 13, 14) .
The most prevalent form of sideroblastic anemia is an acquired disorder found primarily among the elderly, originally designated as primary acquired sideroblastic anemia or idiopathic acquired sideroblastic anemia ( 1) . These disorders are now generally classified as refractory anemia with ringed sideroblasts (RARS), one of the myelodysplastic syndromes (15) , and also a heterogeneous group of disorders. The majority of patients have a trilineage disorder involving erythroid, granulocyte, and megakaryocyte cells, and an increased risk of progression to leukemia ( 16) . However, a "pure sideroblastic anemia" form has been identified with only erythroid dysplasia and a low risk of transformation to acute leukemia (17) (18) (19) (20) (Table II) .
Her white cell count was normal and her platelets were slightly elevated. Bone marrow examination showed gross erythroid hyperplasia with 30% ringed sideroblasts. Of note, she had presented 9 yr earlier with exacerbation of her chronic pulmonary obstructive airways disease, but no hematological abnormalities were found at that time (Table II) Chalfont, UK), 50 mM glycine, 250 mM sucrose, and, unless otherwise indicated, 0.4 mM pyridoxal 5'-phosphate (PLP), (Sigma Chemical Co., St. Louis, MO). Aminolevulinic acid use was inhibited by 2 mM EDTA and 0.1 mM succinylacetone (4,6-dioxoheptanoic acid) (Sigma). Succinyl CoA generation was provided by 0.5 U of succinate thiokinase (Sigma), 5 mM GTP (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ), 1.35 mM CoA (Sigma), and 2 mM MgCl2. The reaction mixture (0.5 ml) was incubated for 1 h at 37°C in a shaking waterbath. 1 U of bone marrow ALAS activity is that amount of enzyme required to synthesize 1 pmol of aminolevulinic acid in 1 h/106 erythroblasts.
Enzyme stability analysis was carried out using lysed bone marrow samples from the patient and from six normal controls. The samples were preincubated at 37°C for 30 min in the assay reaction mixture minus the succinyl CoA generating system, with 0 or 5 mM PLP. After the preincubation period, the assay was initiated by the addition of the succinyl CoA-generating system, [2,3-4C ] succinic acid, and sufficient PLP to give a final concentration of at least 0.4 mM.
PCR, sequence, and restriction analysis. Genomic DNA was extracted by standard techniques (27) from lymphocytes of both patients and from fibroblasts of Patient 2 obtained with informed consent in accord with institutional guidelines. All exons, including the intron/ exon boundaries, 1 kb of promoter region, and 350 nucleotides (nt) 3' of the ALAS2 gene from Patient 1 were PCR-amplified, subcloned, and sequenced as previously described (3). ALAS2 exon 7 was amplified using oligonucleotides; sense, 5 'GCCGCCGAATTCTTIGCCAGG-TCAAACC3', and antisense, 5 'GCCGCCGAATTCGACCAACAC-TAGTAAACAT3', with an annealing temperature of 60°C. Exon 5 from Patient 2 was amplified, subcloned, and sequenced as previously described (8) . The remaining exons from the ALAS2 gene of Patient 2 were sequenced directly from PCR products using solid-phase direct sequencing as described (28) . The cDNA nucleotide numbering was modified from our original sequence (29) to account for an additional 67 nucleotides in exons 1 and 2 identified in the genomic sequence (Bishop, unpublished observations) and not present in the reported cDNA clone.
Confirmation of the K299Q mutation in Patient 1 and screening of other family members was accomplished by BsrI (New England Biolabs Inc., Beverly, MA) restriction of amplified exon 7. In Patient 2, mismatch PCR for confirmation of the A172T mutation was performed with oligonucleotides; sense, 5 'AGACTAGCCAGGGAGAGACT3', and antisense, 5 'GAAATGTTGGGCAAAGGGATATGCATCGG3', with an annealing temperature of 60TC. The underlined nucleotide differed from the normal sequence (5' . . . TCAG 3'), such that an AvaIl restriction site was introduced only into the product amplified from a template containing the G566A mutation. BsrI-restricted exon 7 and AvaII-restricted exon S PCR products were resolved by electrophoresis in 2% agarose gels.
Expression ofrecombinant normal and mutantALAS2. Recombinant normal and mutant ALAS2 were generated using the pMAL fusion protein expression system (New England Biolabs Inc.), resulting in the maltose-binding protein (MBP) attached to the NH2 terminus of ALAS2 with a Factor Xa-cleavable linkage. The A172T and K299Q mutations were introduced into the pMALc2-AE2 expression clone (8) , by sitedirected mutagenesis using the unique site-elimination method (30) . The resulting clones, pMALc2-AE1O (K299Q) and pMALc2-AE13 (A172T), were sequence confirmed for the entire coding region.
The expression constructs were transfected into Escherichia coli BL21, pLysS (Novagen Inc., Madison, WI) and overnight cultures grown in Luria broth (GIBCO BRL, Gaithersburg, MD) medium with 50 pg/ml ampicillin (Sigma) and 34 Mg/ml chloramphenicol (Sigma).
The next day, 200-ml cultures in Luria broth/ampicillin medium were initiated with a 1:40 dilution of the overnight cultures and grown to 0.6-0.8 A.6w U. Induction with 0.4 mM isopropyl /3-D-thiogalactopyranoside was carried out in Luria broth/ampicillin media for 4 h at 37°C. Cells were pelleted at 4,000 g for 15 min. The pellet was resuspended in 5 ml of column buffer (50 mM Hepes, pH 7.5, 1 mM EDTA, 5 mM DTT, 0.2 mM PMSF, and 10 MM PLP), and frozen at -70°C. RNase A (Sigma), DNase I (Sigma), and MgCl2 were added to the thawed lysates to final concentrations of 200 sg/ml, 20 Lg/ml, and 1 mM, respectively. The lysates were incubated for 20 min at room temperature and then centrifuged at 4°C for 30 min at 10,000 g. The supernatants were retained and filtered through a 0.45-Ism filter (Gelman Sciences, Inc., Ann Arbor, MI) to yield the crude E. coli extract. This was then diluted with 3 vol of column buffer and applied to an amylose resin affinity column (New England Biolabs). MBP-ALAS2 fusion proteins were eluted from the column with column buffer containing 10 mM maltose, and stored at -20°C in 50 mM Hepes, pH 7.5, 50% glycerol, 1 mM EDTA, 5 mM DTT, 0.2 mM PMSF, 10 ,M PLP. Crude extract and affinity-purified normal and mutant ALAS2 fusion proteins were analyzed by SDS-PAGE in 10% gels with a 3% stacking gel according to the method of Laemmli and Favre (31) .
Effect of PLP on recombinant normal and mutant ALAS2 activity. The incubation conditions of the ALAS2 assay were as previously described (32) with detection by Ehrlich's reagent after reaction with ethyl acetoacetate (33) . 1 U of recombinant ALAS2 activity is that amount of enzyme required to catalyze the production of 1 nmol of 6-aminolevulinate per h under the conditions of the assay. Protein concentration was determined by a modification of the fluorescamine method (34).
Normal and mutant recombinant MBP-ALAS2 fusion proteins were assayed in 0 or 0.4 mM PLP for 15 min. The activities of the recombinant MBP-ALAS2 fusion proteins were also assessed by preincubating in assay medium minus succinate, plus 0 or 0.2 mM PLP for 30 min before assay. The assay (15 min) was initiated by addition of 1 mM succinate and the PLP concentration was adjusted to 0.4 mM.
Recombinant MBP-ALAS2 fusion proteins eluted from the affinity resin were assessed for protease contamination using a casein-resorufin (Boehringer Mannheim Biochemicals, Indianapolis, IN) assay as described (35) , with modifications as detailed in the manufacturer's instructions. Samples were incubated for 24 h, followed by spectrophotometric assay at A574- This A to C transversion in exon 7, corresponding to nt 947 in the cDNA, predicted a substitution of glutamine for lysine at residue 299 (K299Q), (Fig. 1 A) . The mutation introduced a BsrI restriction site and digestion of the 324-bp PCR product from Patient 1 resulted in fragments of 160, 106, and 58 bp, compared to fragments of 266 and 58 bp in digested PCR products from normal individuals, confirming the mutation in Patient 1. Restriction with BsrI identified the same mutation in his daughter but not in his grandson or two nephews (Fig.  2 A) . The K299Q mutation was not found in 100 alleles from unrelated Caucasian females by BsrI restriction of amplified ALAS2 exon 7 from genomic DNA (data not shown), indicating the mutation was not a common polymorphism. change predicted the substitution of threonine for alanine at residue 172 (A172T). All other exons were further analyzed by direct sequencing of PCR products using solid-phase sequencing, and the base change in exon 5 was the only difference from the normal sequence. Mismatch PCR was used to introduce an AvaII site into PCR products from Patient 2. Restriction with AvaiH resulted in fragments of 156 and 31 bp from the mutant allele, whereas the PCR product derived from the normal allele of Patient 2 (187 bp) remained uncut (Fig. 2 B) . Mismatch PCR and restriction of DNA from fibroblasts of Patient 2 also demonstrated the presence of the base change (Fig. 2  B) , indicating that this was a constitutive change rather than a somatic mutation. Analysis of genomic DNA from the patient's daughter revealed that she was not a carrier of the A172T mutation (Fig. 2 B) . The A172T mutation was not a common polymorphism as indicated by its absence in 100 normal alleles by mismatch PCR and restriction analysis (data not shown).
ALAS activity in bone marrow from Patient 2 was in the normal range and was inactivated (43%), as was the normal enzyme (40%), when assayed in the absence of PLP (Table  HI) . Similarly, when the bone marrow erythroblast lysates were preincubated without PLP for 30 min at 370C before assaying, the normal enzyme lost 55% of its activity relative to preincubation in the presence of PLP. In contrast, even in the presence of 5 mM PLP, the preincubated mutant enzyme from Patient 2 lysate lost 68% of its activity (Table III) .
Expression and characterization of recombinant normal and mutant AL4S2. Recombinant normal, K299Q, and A172T ALAS2 were expressed in E. coli as fusion proteins with MBP using the pMAL expression system, as described in the Methods. Expression resulted in > 10% of the ALAS2 fusion protein remaining soluble in the supernatant by SDS-PAGE gel electrophoresis (data not shown). Affinity purification of soluble MBP-ALAS2 fusion proteins resulted in > 90% purity (Fig. 3) . (Table IV) . In contrast to the bone marrow assay, the recombinant normal and mutant enzymes were both stable without added PLP in the assay. Interestingly, the specific activities of the affinity-purified mutant enzymes were higher than the normal enzyme, consistent with the bone marrow data from Patient 2 that showed normal ALAS activity.
As was the case in the bone marrow assay, preincubation of the normal recombinant enzyme for 30 min at 37TC in the absence of added PLP resulted in a 56% loss of activity, with 0.2 mM PLP preventing inactivation (Table IV) . In contrast to the bone marrow result, addition of only 0.2 mM PLP substantially protected the mutant recombinant enzymes from inactivation during preincubation. In vitro, the Patient 2 mutant recombinant enzyme was significantly more unstable than the normal enzyme to preincubation minus PLP, losing 94% of its activity. Patient 1 recombinant enzyme was also less stable than the normal enzyme under these conditions. To evaluate whether the observed loss of activity during preincubation in the absence of PLP was due to contaminating protease activity, each of the enzyme solutions eluted from the affinity column was incubated for 24 h with a casein-resorufin proteolytically chromogenic substrate as described in the Methods. No protease activity was detected in any sample. The assay was sensitive enough to detect 1 pg/ml trypsin (Sigma).
Discussion
The two patients reported here initially were diagnosed as having the acquired disorder RARS. However, these patients were unusual in that they had hypochromic, microcytic erythrocytes and their anemia was corrected by pyridoxine therapy. Neither (Table I) , but a few hypochromic, microcytic erythrocytes remained. In Patient 2, treatment with 600 mg/d of pyridoxine and subsequent maintenance on 50 mg/d completely normalized her erythrocyte values (Table II) . Notably, the bone marrow became free of ringed sideroblasts and detailed examination of peripheral blood films failed to find any evidence of hypochromic, microcytic erythrocytes. Complete remission of anemia in pyridoxine-responsive sideroblastic anemia patients is most unusual.
Pyridoxine-responsiveness and erythrocyte microcytosis suggested that the underlying defect might be XLSA. Thus, genomic DNA from each patient was isolated and the AL4S2 coding region and adjacent intron/exon boundary sequences were analyzed. Patient 1 had a single nucleotide change in exon 7, an A to C transversion that predicted a lysine to glutamine substitution at codon 299 (K299Q). This is the first instance of an exon 7 mutation in XLSA. That the K299Q mutation also was found in his daughter indicated the inherited rather than acquired nature of this lesion. In Patient 2, a single point mutation was identified in exon 5; a G to A transition that predicted the substitution of threonine for alanine at codon 172 (A172T). The A172T mutation was not a somatic mutation of the bone marrow as it was present in DNA extracted from both the patient's lymphocytes and skin fibroblasts. Thus, the remarkable presentation of XLSA in the eighth and ninth decades of life expands the clinical phenotype and defines a variant late-onset form of XLSA due to mutations of the AL4S2 gene, a diagnosis which should be considered in the evaluation of patients with microcytic erythrocytes thought to have RARS.
The dramatic normalization of hemoglobin levels with pyridoxine therapy in these patients suggested that both the K299Q and A172T mutations resulted in particularly B6-responsive forms of ALAS2 deficiency. Evidence in support of this hypothesis was obtained from stability studies using highly purified recombinant normal and mutant ALAS2 (Table IV) . Both recombinant mutant enzymes preincubated for 30 min at 37°C in the absence of PLP were much less stable than normal enzyme preincubated without PLP. Preincubation with 0.2 mM PLP substantially protected these enzymes from inactivation suggesting a mechanism for the observed dramatic pyridoxine re- (38) described the increased susceptibility to a specific mitochondrial protease of apo-ALAS from bone marrow of patients with pyridoxine-responsive XLSA. On the other hand, the maltose-binding protein moiety could be a stabilizing influence on the recombinant enzymes. Nonetheless, the presence of the maltose-binding protein moiety of the fusion protein did not exert a major effect on the ALAS2 enzymatic activity as the normal ALAS2 fusion protein had unchanged activity after cleavage with Factor Xa (data not shown). No detectable proteolytic activity was found in the affinity-purified enzyme samples, suggesting that the loss of activity during preincubation was due to inherent thermolability and not due to protease activity.
Interestingly, without preincubation, the mutant enzyme activity was normal in the bone marrow assay, even though the patient presented with a Hb of 4.2 g/dl. Bottomley et al. (39) reported a higher than normal level of ALAS activity in bone marrow from some sideroblastic anemia patients. Since the bone marrow assay measures both cytoplasmic and mitochondrial ALAS2 activity, in Patient 2 the cytoplasmic activity could be high relative to normal individuals but still result in normal total activity if the mitochondrial activity was low. Thus it is possible that Patient 2 (A172T) was producing increased amounts of enzyme, as might be expected by release of translation inhibition with high iron levels (40) , and/or mutant enzyme with higher specific activity (Table IV) while the mutant enzyme was markedly unstable and subject to rapid inactivation before or in the course of mitochondrial import. Since only the mitochondrial enzyme has access to substrates in vivo, this would result in reduced heme biosynthesis and anemia.
A decline in PLP availability or metabolism may have precipitated the late-onset of XLSA in these patients. An agerelated decline in pyridoxine metabolism in combination with a reduced vitamin intake has been described in elderly populations (41, 42 (24) . In addition, several other cases of middle-aged/elderly individuals with pyridoxine responsive RARS have been reported (10, 39) . These cases had a clinical course suggestive of late-onset XLSA due to mutations of ALAS2. The identification of inherited ALAS2 mutations in the two late-onset patients reported here resulted in a clear rationale for pyridoxine therapy and a reduction of their anxiety since XLSA does not progress to leukemia.
These cases emphasize the importance of evaluating all acquired sideroblastic anemia patients for pyridoxine responsiveness, irrespective of sex or age, particularly if they have microcytic red cells. Careful studies of erythrocyte size distribution in family members may be helpful. A diagnosis of sideroblastic anemia with microcytic, hypochromic erythrocytes and especially a positive response to pyridoxine warrants further investigation for ALAS2 mutations. Once a specific lesion is identified, genetic studies are indicated for family members with no obvious hematologic abnormality but who nevertheless may be latent carriers of XLSA.
